M oyamoya syndrome (MMS) is a rare chronic occlusive cerebrovascular disorder in children characterized by a progressive stenosis or occlusion of the internal carotid artery and proximal cerebral arteries with an extensive network of cerebral collaterals. 1, 2 Although primary and secondary forms associated with a variety of entities have been recognized, its origin remains undetermined. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] The contribution of prothrombotic disorders to the pathogenesis of MMS in children is still to be elucidated because available data are related only to retrospective studies of few patients. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] The main aim of this work was to perform a prospective study, including a complete hemostatic evaluation, to determine the frequency of prothrombotic disorders in a pediatric population with MMS.
Subjects and Methods
From May 1992 to April 2000, a prospective study of 80 consecutive children with arterial ischemic stroke (AIS; age range, 1 month to 18 years) referred for study to our department was carried out. Ten fulfilled the angiographic criteria of MMS (6 girls, 4 boy; median age, 6.6 years; range, 1.0 to 14.9 years). The diagnosis of MMS by cerebral angiography showed bilateral stenosis or occlusion of the distal internal carotid and proximal cerebral arteries associated with
See Editorial Comment, page 1791
an abnormal network of collateral vessels at the base of the brain. Patients with primary and secondary forms of MMS were included in this study.
Data concerning clinical presentation, underlying diseases and/or circumstantial risk factors, radiological findings, family history of thrombosis, treatment, and outcome were recorded.
After parental informed consent was obtained, blood samples were collected into 0.11 mol/L sodium citrate at a ratio of 9:1 by clean venipuncture. Blood was centrifuged at 2500g for 15 minutes. Platelet-poor plasma was immediately processed or stored at Ϫ70°C.
Evaluation for prothrombotic disorders included the following assays in all patients: prothrombin time; activated partial thromboplastin time; thrombin time; reptilase time; fibrinogen; and factors V, VIII, and XII activity by standard procedures. Functional activities of protein C, antithrombin, and plasminogen were measured by amidolytic assays (chromogenic substrates, Chromogenix AB) and protein C and protein S by clotting assays with a model ST4 coagulometer (Diagnostica Stago). Immunological measurements of protein C, protein S (total and free), antithrombin, and plasminogen were made by Laurell's technique 26 with polyclonal rabbit antibodies against the respective antigens (protein C, protein S, and antithrombin, Dakopatts; ASSERA plasminogen, Diagnostica Stago). Free protein S was assayed by precipitating bound protein with polyethylene glycol 8000 (3.75%) for 30 minutes at 4°C, followed by electroimmunoassay according to the method by Comp et al. 27 Free protein S was expressed in units per milliliter and calculated by extrapolation from a standard curve constructed with serial dilutions of normal pool plasma calibrated against a reference preparation code 93/590 from the National Institute for Biological Standards and Control (Hertfordshire, United Kingdom) in which the free protein S level of the pool was 0.98 U/mL. Presence of activated protein C resistance was tested by use of a commercial kit with factor V-deficient plasma as a prediluent for plasma samples (Chromogenix AB). DNA analyses for the factor V Leiden and prothrombin gene mutations were performed as previously described. 28, 29 Children having a thrombotic episode before 1994 were called again at a later date for the last 2 tests. The presence of a lupus anticoagulant (LA) was determined on the basis of abnormal screening assays, mixing studies, and confirmatory assays based on the method giving abnormal screening tests results. 30 The specific tests used were activated partial thromboplastin time (locally produced brain cephalin) and diluted Russell viper venom time (Sigma-Aldrich) with confirmation from the platelet neutralization procedure, 31 as recommended by the International Society on Thrombosis and Haemostasis. 32 Anticardiolipin antibodies (ACA) IgG and IgM isotypes were performed (Coaliza AntiCardiolipin IgG and IgM, Chromogenix AB), calibrated against Dr Harris' standards from the University of Louisville, Kentucky. Serum samples with IgG and IgM values Ͻ10 GPL/MPL were defined as negative, 10 to 20 GPL/MPL as positive at low levels, 20 to 80 GPL/MPL as positive at moderate levels, and Ͼ80 GPL/MPL as positive at high levels. 32 IgG anti-␤ 2 -glycoprotein I (␤ 2 -GPI) antibodies were assayed by ELISA technique with a commercial kit (QUANTA Lite ␤ 2 GPI IgG, Inova Diagnostics). The results were expressed in IgG anti-␤ 2 -GPI units. Values Ͼ20 IgG anti-␤ 2 -GPI units were considered abnormal.
According to proposed criteria for the antiphospholipid syndrome (APS), only those patients with AIS and positive LA test results and/or positive IgG and/or IgM ACA at moderate to high levels (Ͼ20 GPL or MPL units) in 2 determinations performed Ͼ8 weeks apart were considered positive for APS. 32 In children with suspected inherited prothrombotic disorders, the final diagnosis was made when repeatedly measured plasma concentrations of the coagulation proteins investigated (3 to 6 months after the thrombotic episode) were outside the age-appropriate reference range and the findings in family studies of abnormal laboratory results confirmed the suspected inherited coagulation defect. LA, ACA, and anti-␤ 2 -GPI antibodies were tested within 1 week of the thrombotic event in all cases. In our study, subsequent controls for LA, ACA, and anti-␤ 2 -GPI antibodies were done every 2 months in children with APS to control the time course of these abnormal results. Their parents were also studied to discard familial APS.
To establish the normal laboratory reference values, 100 healthy adults (50 men, 50 women; mean age, 37.2 years; range, 25 to 49 years) receiving no medications were studied. With informed parental consent, 60 healthy children (33 boys, 27 girls; mean age, 8.6 years; range, 1 to 16 years) admitted to the hospital for elective minor surgery or as potential bone marrow donors were eligible for normal reference ranges. The children were gathered in groups of 20 individuals 1 to 5, 6 to 10, and 11 to 16 years of age.
A positive family history of thrombosis required a first-and/or second-degree relative with thrombosis at a young age (Ͻ45 years).
Results
The median age at diagnosis was 6.6 years. A female predominance was found. No patient was of Asian descent. All patients had multiple AIS; 1 patient with an anterior communicating artery aneurysm also had an intracranial hemorrhage. Table 1 shows the baseline demographics, underlying diseases, risk factors, clinical features at presentation, radiological findings, family history of thrombosis, treatment, and outcome of the patients studied.
Inherited and acquired prothrombotic disorders were detected in 4 (40%) of the 10 children studied. In our series, inherited protein S deficiency was found in 1 patient; LA and ACA were detected in the remaining 3 patients. One of them presented with persistent LA for 2.7 years until his death. In the case of the other 2 patients, until now, 1 has maintained LA for 9 months, and the other has kept ACA/anti-␤ 2 -GPI antibodies for 10 months. LA and ACA tested repeatedly every 2 months showed the persistence of a similar pattern of laboratory features (screening and confirmatory tests) in the 2 patients with LA and stable ACA/anti-␤ 2 -GPI antibodies values in the remaining patient. The laboratory findings of these patients are summarized in Table 2 .
The child with common variable immunodeficiency died of cerebral hemorrhage after developing a severe coagulopathy for liver insufficiency.
Two patients underwent surgical revascularization (encephaloduroarteriosynangios); 1 died 3 days after the surgery given that revascularization failed to halt the progression of cerebral ischemia, whereas the other is still alive and has had progressive improvement after the procedure. The remaining 7 patients are alive with follow-up periods ranging from 5 to 107 months (median, 26 months). These children have received aspirin and have developed different kinds of disabilities (data shown in Table 1 ).
Discussion
MMS has been described in all ethnic groups but remains rare outside Japan. [2] [3] [4] 33 In the western hemisphere, it is most often related to another underlying condition. 3,6 -8 In our series, 40% of the patients had an associated disease; 1 presented with common variable immunodeficiency, an entity that has not yet been reported in patients with MMS. Most of our patients were Ͻ10 years of age, and AIS or transient ischemic attack was the predominant initial complications, as in other pediatric series. [2] [3] [4] [5] Aneurysm, detected in only 1 of our patients, has rarely been described in children. 2, 3 The origin of MMS remains undetermined. It is not clear whether it is a congenital arterial dysplasia or a syndrome caused by nonspecific vascular reaction. 10 -14 Genetic factors have been suggested to contribute to the origin in some familial or sporadic cases of MMS in the Japanese population. 6, 34, 35 However, natural inhibitors of the coagulation are encoded by genes located in chromosomes that have not yet been involved in MMS. Strong HLA class II antigen correlations have been found for several autoantibodies, including LA and ACA, in patients with some autoimmune diseases. 36 Therefore, further studies are necessary to clarify multiple genetic factors that are definitely linked with MMS in different ethnic groups.
Inherited and acquired prothrombotic disorders have been identified as a cause of AIS in young people. [37] [38] [39] Several genetic defects contribute to increase the risk of thrombosis. 40 Among them, inherited protein S deficiency has been related to arterial thrombotic complications. [41] [42] [43] [44] [45] [46] However, this abnormality as a prothrombotic disorder is still a controversial issue. 40, 47 It has been reported that the levels of protein S are influenced by sex, age, pregnancy, and hormonal state. 47 In our study, we applied separate local laboratory reference ranges for women and men in the assessment of protein S levels in the families studied. Concerning acquired disorders, APS is a heterogeneous group of autoantibodies that includes LA and ACA, which are strongly associated with arterial and venous thrombosis. 48 In patients with APS, the vast majority of antibodies detected in conventional anticardiolipin assays bind to epitopes on ␤ 2-GPI. 49 -51 The endothelial cell interaction with these antibodies has been proposed as a probable mechanism to predispose to thrombosis. 48, 52 Endothelial cell alterations in the vasculopathy of MMS may be a source of autoantigens that drive that autoimmune response. An underlying autoimmune condition, as described in Down's syndrome, inducing the appearance of these antibodies and a progressive vascular damage, could not be discarded. 21 Variable frequency of prothrombotic disorders has been reported in non-MMS children with AIS 17, 37, 38, 53 ; in our previous study, we found these abnormalities in 7 of the 30 children (23%) evaluated. 39 Few reports have described the probable relationship between hemostatic abnormalities and MMS. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] In our series, a prothrombotic disorder was detected in 4 of our patients (40%). Inherited protein S deficiency was detected in 1 patient, and persistent positive LA or ACA was found for months or even years in the remaining 3 patients.
Optimal treatment of childhood AIS and prothrombotic disorders is still controversial. 54 Surgery using different revascularization methods has improved the outcome of MMS patients. 55 However, in children with MMS and hypercoagulable state, whether or not surgery has been performed, prophylaxis and treatment with antithrombotic agents have been recommended. 54 Only controlled clinical trial of these pediatric patients could establish whether these therapies can reduce the frequency of thrombotic events and ameliorate the cognitive dysfunction. We report the hemostatic data of the largest prospective study of pediatric patients with MMS carried out at a single center in the western hemisphere. A large, prospective, multicenter study is required to define the pathogenic significance of these prothrombotic abnormalities and determine the most appropriate therapy in these children. APTT indicates activated partial thromboplastin time; dRVVT, diluted Russell viper venom time. Local laboratory reference ranges of free, total, and clotting assays of protein S according to age and sex are shown in parentheses.
prothrombotic disorders and moyamoya disease. The recent formation of a childhood stroke study group in conjunction with the National Institute for Neurological Disorders and Stroke will enable large multicenter studies to elucidate the mechanisms and optimal treatment strategies for this and other types of childhood stroke.
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